Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Karonudib in Hematological Malignancies
NCT04077307Phase 1Recruiting
- Sponsor
- Thomas Helleday Foundation
- Start
- Dec 2019
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of karonudib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and 3 more, sponsored by Thomas Helleday Foundation. Primary endpoints: Safety of Karonudib (TH1579) at 28 days and Tolerability of Karonudib (TH1579) at 28 days. Started Dec 2019; status: recruiting.
02
Drugs
karonudib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04077307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04077307.